Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge

Antiviral Research

Volumn 98, Issue 2, 2013, Pages 135-143

  Gowen, Brian B ^a   Bailey, Kevin W ^a   Scharton, Dionna ^a   Vest, Zachery ^a   Westover, Jonna B ^a   Skirpstunas, Ramona ^a,b   Ikegami, Tetsuro ^c,d  

^a UTAH STATE UNIVERSITY   (United States)

^b State of Utah ^*  (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Phlebovirus; Post exposure vaccination; Rift Valley fever virus; Treatment; Viral hemorrhagic fever

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA INTERFERON; MP 12 VACCINE; PLACEBO; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; VIRUS VACCINE; LIVE VACCINE; VIRUS PROTEIN; NSS PROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN DISEASE; CAUSE OF DEATH; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FUNCTION; HISTOPATHOLOGY; INFECTION PREVENTION; LIMIT OF DETECTION; LIVER; LIVER INJURY; LYMPHOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RIFT VALLEY FEVER; RIFT VALLEY FEVER BUNYAVIRUS; SPLEEN; VIRUS ATTENUATION; VIRUS LOAD; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE; ANIMAL; C57BL MOUSE; GENETICS; HUMAN; IMMUNOLOGY; PHYSIOLOGY; VACCINATION; VIROLOGY; ANTIVIRAL ACTIVITY; PROVOCATION TEST; VIREMIA;

MUS; PHLEBOVIRUS; RIFT VALLEY FEVER VIRUS;

ANIMALS; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; POST-EXPOSURE PROPHYLAXIS; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; VACCINATION; VACCINES, ATTENUATED; VIRAL NONSTRUCTURAL PROTEINS; VIRAL VACCINES; VIRUS REPLICATION;

EID: 84875969188     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.03.009     Document Type: Article

References (29)

1. Billecocq A., Gauliard N., Le May N., Elliott R.M., Flick R., Bouloy M. RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses. Virology 2008, 378:377-384.
2. Bird B.H., Ksiazek T.G., Nichol S.T., Maclachlan N.J. Rift Valley fever virus. J. Am. Vet. Med. Assoc. 2009, 234:883-893.
3. Borio L., Inglesby T., Peters C.J., Schmaljohn A.L., Hughes J.M., Jahrling P.B., Ksiazek T., Johnson K.M., Meyerhoff A., O'Toole T., Ascher M.S., Bartlett J., Breman J.G., Eitzen E.M., Hamburg M., Hauer J., Henderson D.A., Johnson R.T., Kwik G., Layton M., Lillibridge S., Nabel G.J., Osterholm M.T., Perl T.M., Russell P., Tonat K. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002, 287:2391-2405.
4. Caplen H., Peters C.J., Bishop D.H. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J. Gen. Virol. 1985, 66:2271-2277.
5. CDC Rift Valley fever outbreak-Kenya, November 2006-January 2007. MMWR Morb. Mortal. Wkly Rep. 2007, 56:73-76.
6. Gowen B.B., Ennis J., Sefing E.J., Wong M.H., Jung K.H., Turner J.D. Extended protection against phlebovirus infection conferred by recombinant adenovirus expressing consensus interferon (DEF201). Antimicrob. Agents Chemother. 2012, 56:4168-4174.
7. Gowen B.B., Wong M.H., Jung K.H., Sanders A.B., Mendenhall M., Bailey K.W., Furuta Y., Sidwell R.W. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 2007, 51:3168-3176.
8. Gray K.K., Worthy M.N., Juelich T.L., Agar S.L., Poussard A., Ragland D., Freiberg A.N., Holbrook M.R. Chemotactic and inflammatory responses in the liver and brain are associated with pathogenesis of Rift Valley fever virus infection in the mouse. PLoS Negl. Trop. Dis. 2012, 6:e1529.
9. Ikegami T., Makino S. Rift valley fever vaccines. Vaccine 2009, 27(Suppl. 4):D69-72.
10. Ikegami T., Makino S. The pathogenesis of Rift Valley fever. Viruses 2011, 3:493-519.
11. Ikegami T., Narayanan K., Won S., Kamitani W., Peters C.J., Makino S. Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog. 2009, 5:e1000287.
12. Ikegami T., Won S., Peters C.J., Makino S. Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J. Virol. 2006, 80:2933-2940.
13. Jansen van Vuren P., Tiemessen C.T., Paweska J.T. Anti-nucleocapsid protein immune responses counteract pathogenic effects of Rift Valley fever virus infection in mice. PLoS ONE 2011, 6:e25027.
14. Le May N., Dubaele S., Proietti De Santis L., Billecocq A., Bouloy M., Egly J.M. TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. Cell 2004, 116:541-550.
15. Le May N., Mansuroglu Z., Leger P., Josse T., Blot G., Billecocq A., Flick R., Jacob Y., Bonnefoy E., Bouloy M. A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. PLoS Pathog. 2008, 4:e13.
16. Lihoradova O., Kalveram B., Indran S.V., Lokugamage N., Juelich T.L., Hill T.E., Tseng C.T., Gong B., Fukushi S., Morikawa S., Freiberg A.N., Ikegami T. The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine. J. Virol. 2012, 86:7650-7661.
17. McElroy A.K., Nichol S.T. Rift Valley fever virus inhibits a pro-inflammatory response in experimentally infected human monocyte derived macrophages and a pro-inflammatory cytokine response may be associated with patient survival during natural infection. Virology 2012, 422:6-12.
18. Morrill J.C., Jennings G.B., Caplen H., Turell M.J., Johnson A.J., Peters C.J. Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes. Am. J. Vet. Res. 1987, 48:1042-1047.
19. Morrill J.C., Mebus C.A., Peters C.J. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am. J. Vet. Res. 1997, 58:1104-1109.
20. NIAID, 2006. National Institute of Allergy and Infectious Diseases Biodefense Research Agenda for CDC Category A Agents, In: NIAID (Ed.). NIAID, Bethesda, MD.
21. Pepin M., Bouloy M., Bird B.H., Kemp A., Paweska J. Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet. Res. 2010, 41:61.
22. Peters C.J., Reynolds J.A., Slone T.W., Jones D.E., Stephen E.L. Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral Res. 1986, 6:285-297.
23. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27:493-497.
24. Rusnak J.M., Byrne W.R., Chung K.N., Gibbs P.H., Kim T.T., Boudreau E.F., Cosgriff T., Pittman P., Kim K.Y., Erlichman M.S., Rezvani D.F., Huggins J.W. Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea. Antiviral Res. 2009, 81:68-76.
25. Russmann S., Grattagliano I., Portincasa P., Palmieri V.O., Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr. Med. Chem. 2006, 13:3351-3357.
26. Schmaljohn C., Nichol S.T. Bunyaviridae. Fields Virology 2007, 1741-1789. Lippincott Williams & Wilkins, Philadelphia. fifth ed. D.M. Knipe, P.M. Howley, D.E. Griffin, R.A. Lamb, M.A. Martin, B. Roizman, S.E. Straus (Eds.).
27. Smith D.R., Steele K.E., Shamblin J., Honko A., Johnson J., Reed C., Kennedy M., Chapman J.L., Hensley L.E. The pathogenesis of Rift Valley fever virus in the mouse model. Virology 2010, 407:256-267.
28. Turell M.J., Wilson W.C., Bennett K.E. Potential for North American mosquitoes (Diptera: Culicidae) to transmit rift valley fever virus. J. Med. Entomol. 2010, 47:884-889.
29. Wilson M.L. Rift Valley fever virus ecology and the epidemiology of disease emergence. Ann. N. Y. Acad. Sci. 1994, 750:169-180.